



<b>Study Title:</b>	Treatment Trial for Asymptomatic High-Risk Smoldering Multiple Myeloma
<b>Scientific Title:</b>	Randomized Phase III Trial of Lenalidomide vs. Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
<b>Department and/or Specialty:</b>	RCC – HEME – Multiple Myeloma
<b>Investigator:</b>	Michael Thompson, MD, PhD
<b>Contact Information:</b>	Chanda Miller 262-928-5539
<p>Biological therapies such as lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient.</p> <p>This phase III trial is studying lenalidomide to see how well it works compared to observation in treating patients with asymptomatic high-risk smoldering multiple myeloma.</p>	



**PROHEALTH CARE**  
RESEARCH INSTITUTE